DEF: CAMP4 Therapeutics Sets 2026 Annual Meeting Date

CAMP4 Therapeutics Corporation announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026, with key proposals including director elections and an amendment to its equity incentive plan.

Summary

• CAMP4 Therapeutics Corporation is holding its 2026 Annual Meeting of Stockholders on June 10, 2026, at 11:00 a.m. Eastern Daylight Time via a live webcast.
• The meeting will cover the election of three Class II directors: Steven Holtzman, Murray Stewart, DM FRCP, and Richard Young, PhD, each for a three-year term.
• Stockholders will also vote on ratifying the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• A proposal to approve an amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan is also on the agenda.
• The record date for determining stockholders entitled to vote is April 13, 2026.
• Proxy materials will be made available over the Internet, with notices to be sent on or about April 23, 2026.
• The meeting will be conducted virtually, and stockholders can participate and vote online.
• Michael Higgins will not be standing for re-election as a Class II director, and his term will expire at the meeting, reducing the Board size to eight members.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and a proactive approach to talent management through equity incentives, with no immediate negative financial indicators presented.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The proposed amendment to the equity incentive plan aims to ensure a sufficient number of shares are available for attracting and retaining talent, which is crucial for growth.
• The board composition includes experienced individuals with strong backgrounds in the biopharmaceutical industry.
• The company has a clear process for director nominations and stockholder proposals.

Negatives

• Michael Higgins, a Class II director, is not standing for re-election, which will reduce the Board size.
• The company is an emerging growth company, which allows for scaled disclosure but also indicates a relatively early stage of development.
• The filing details past loans to related persons (Mandel-Brehm and Gold) that were forgiven, along with associated tax bonus payments, which could be perceived as a related-party concern.

Risks

• The amendment to the equity incentive plan is necessary because the current calculation method for share increases does not adequately account for pre-funded warrants, potentially limiting the company's ability to attract and retain talent.
• Failure to approve the amendment to the equity incentive plan could limit the number of shares available, negatively impacting the ability to attract and retain employees.
• The company's reliance on equity compensation to attract and retain talent could be impacted if the plan amendment is not approved.
• The company is subject to Nasdaq Listing Rules regarding director independence and committee composition.
• The company has adopted a clawback policy for incentive compensation in case of financial restatements.

Future Outlook

The company is seeking stockholder approval for an amendment to its 2024 Equity Incentive Plan to ensure a sufficient number of shares are available for future equity grants, which is crucial for attracting and retaining talent as the company scales its growth and progresses its research and clinical candidates. The amendment is expected to provide equity incentives for at least the next several years.

Management Comments

• "We are pleased to notify you that we will hold the 2026 annual meeting of the stockholders (the Annual Meeting) of CAMP4 Therapeutics Corporation (CAMP4, we, us, or our) via live webcast on June 10, 2026, at 11:00 a.m. Eastern Daylight Time in a virtual meeting format."
• "Whether you plan to attend the Annual Meeting or not, it is important that you cast your vote either by remote communication at the virtual meeting or by proxy in advance of the meeting."
• "We encourage you to vote by proxy so that your shares will be represented and voted at the Annual Meeting, whether or not you can attend the virtual meeting."
• "We thank Mr. Higgins for his many years of distinguished service to the Company and our Board."
• "We believe that our equity-based compensation program enables us to maintain our competitive position regarding recruiting and retaining highly skilled and engaged personnel."

Industry Context

StockSavvy.ai notes that CAMP4 Therapeutics, operating in the competitive biotechnology sector, is proactively addressing its equity compensation strategy. The proposed amendment to the 2024 Equity Incentive Plan reflects a common practice among growth-stage biotech companies to ensure they can effectively attract and retain key scientific and management talent, which is critical for advancing drug development pipelines.

Management Changes

Corporate Governance

Related Party Transactions

• The filing details the forgiveness of promissory notes issued to CEO Josh Mandel-Brehm and CFO Kelly Gold in August 2021, along with cash bonuses paid in January 2025 to assist with taxes incurred due to the forgiveness.
• Several directors and executive officers, along with entities affiliated with them, participated in the company's initial public offering in October 2024 and a private placement in September 2025.
• Richard Young, PhD (Director), Josh Mandel-Brehm (CEO), Kelly Gold (CFO), and Yuri Maricich, MD (CMO) purchased shares in the September 2025 private placement.
• The company has a written related person transaction policy reviewed by the audit committee.

Stakeholder Impact

• Stockholders will vote on director elections and the equity incentive plan amendment, directly impacting corporate governance and future equity dilution.
• Employees and potential hires will be impacted by the proposed amendment to the equity incentive plan, which aims to ensure competitive compensation packages.
• The ratification of Ernst & Young LLP as the independent auditor affects the reliability of financial reporting for all stakeholders.

Next Steps

• Stockholders are urged to vote by proxy or remotely at the virtual meeting.
• The company will hold its 2026 Annual Meeting of Stockholders on June 10, 2026.
• The proposed amendment to the 2024 Equity Incentive Plan will be voted on at the Annual Meeting.
• The company will provide a webcast replay of the Annual Meeting on its website.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results or significant strategic shifts that would warrant a change in investment recommendation. The proposals are standard for corporate governance and operational continuity.

Keywords

CAMP4 Therapeutics, Proxy Statement, Annual Meeting, Stockholders, Director Election, Equity Incentive Plan, Ernst & Young LLP, Corporate Governance, Virtual Meeting, SEC Filing